Catalent (CTLT) Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 sell rating, 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTLT, but not buy additional shares or sell existing shares.
View CTLT analyst ratings or view top-rated stocks.

13 analysts have issued 12 month price objectives for Catalent's stock. Their CTLT share price forecasts range from $43.00 to $85.00. On average, they predict the company's share price to reach $53.58 in the next twelve months. This suggests a possible upside of 18.2% from the stock's current price.
View analysts price targets for CTLT or view top-rated stocks among Wall Street analysts.

Catalent's stock was trading at $45.01 at the start of the year. Since then, CTLT shares have increased by 0.7% and is now trading at $45.34.
View the best growth stocks for 2023 here.

Catalent saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 10,990,000 shares, an increase of 5.2% from the August 15th total of 10,450,000 shares. Based on an average daily volume of 2,920,000 shares, the short-interest ratio is presently 3.8 days.
View Catalent's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our CTLT earnings forecast.

Catalent, Inc. (NYSE:CTLT) issued its quarterly earnings results on Tuesday, August, 29th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by $0.02. The firm earned $1.09 billion during the quarter, compared to analyst estimates of $1.05 billion. Catalent had a negative net margin of 5.43% and a positive trailing twelve-month return on equity of 3.24%. The business's quarterly revenue was down 15.6% on a year-over-year basis. During the same quarter last year, the company earned $1.12 earnings per share.
Read the conference call transcript.

ETFs with the largest weight of Catalent (NYSE:CTLT) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL), Invesco Biotechnology & Genome ETF (PBE), iShares U.S. Pharmaceuticals ETF (IHE), VanEck Pharmaceutical ETF (PPH), Invesco S&P 500 Equal Weight Health Care ETF (RYH), Invesco S&P 500 Equal Weight Health Care ETF (RSPH) and WisdomTree BioRevolution Fund (WDNA).

Catalent updated its FY 2024 earnings guidance on Tuesday, August, 29th. The company provided earnings per share (EPS) guidance of $0.62-$0.96 for the period, compared to the consensus estimate of $1.14. The company issued revenue guidance of $4.30 billion-$4.50 billion, compared to the consensus revenue estimate of $4.19 billion.

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital World Investors (8.85%), BlackRock Inc. (8.28%), State Street Corp (4.18%), Veritas Asset Management LLP (3.76%), Veritas Asset Management LLP (3.76%) and Geode Capital Management LLC (2.16%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Charles Lickfold, Gregory T Lucier, John J Greisch, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michael J Grippo, Michelle R Ryan, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano, Thomas W Hawkeswood and Wetteny Joseph.
View institutional ownership trends.

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CTLT stock can currently be purchased for approximately $45.34.

Catalent (NYSE:CTLT) has a market capitalization of $8.17 billion and generates $4.28 billion in revenue each year. The company earns $-232,000,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis.

The company employs 19,000 workers across the globe.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for the company is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at investors@catalent.com, or via fax at 732-537-6480.